Exilby Whole Plant Botanical Cannabis Treatment, Receives Marketing Authorization In Germany; United States FDA Grants Breakthrough Therapy Designation | News & Events

[#item_full_content] In a series of major industry milestones, this week it was announced that the investigational drug Exilby, a standardized full-spectrum extract from a proprietary cannabis strain, has received marketing authorization from Germany for the treatment of chronic low back pain with a neuropathic component while late last month the United States Food & Drug Administration granted the medicine a Breakthrough Therapy Designation intended to expedite the development and evaluation of the drug. It is positioned as the first non-opiate chronic pain treatment of its kind worldwide. Read More